Gyala Therapeutics Unveils Promising CAR-T Therapy Targeting CD84

Gyala Therapeutics has announced preclinical results demonstrating the efficacy of its CAR-T therapy, GYA01, targeting the CD84 protein in leukemia, announced in a press release. This study is the first to present preclinical data on CAR-T cells aimed at CD84, positioning GYA01 as a promising therapy for acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL).

The preclinical findings highlight GYA01's strong and specific cytotoxicity against AML, T-ALL, and aggressive B-cell lymphoma cell lines, as well as primary patient samples. The therapy also showed significant efficacy in animal models, eradicating the disease and extending survival times. Additionally, GYA01 demonstrated robust expansion from both healthy donor and patient T-cells, with a favorable memory phenotype and without the need for gene editing to prevent fratricide.